RxDoctor Payments Data

Kate Dolezal

Family · Amarillo, TXNPI 1225613862

Payments from drug & device makers

$1,179in general payments, 2019–2025

Across 45 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$249
  • Sanofi$175
  • Johnson & Johnson$144
  • Cleerly, Inc.$128
  • Boston Scientific$99
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • plus $327 from 14 others

What the payments were for

  • Food & beverage$1,179100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,179 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$40,806
Medicare patients
135
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide17$18,405
OzempicSemaglutide13$11,501
Combivent RespimatIpratropium/Albuterol Sulfate11$5,293
Armour ThyroidThyroid,pork40$3,050
ProgesteroneProgesterone, Micronized58$1,720
Np ThyroidThyroid,pork22$1,361
Levothyroxine Sodium60$698
Albuterol Sulfate HfaAlbuterol Sulfate21$483
Gabapentin29$470
Atorvastatin Calcium49$336
Acetaminophen-CodeineAcetaminophen With Codeine13$312
Liothyronine Sodium11$258
Olmesartan Medoxomil15$218
Pantoprazole Sodium17$203
Losartan Potassium27$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$249$18,40517 claims
AbbVieArmour Thyroid$24$3,05040 claims
Acella Pharmaceuticals, LLCNp Thyroid$19$1,36122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →